Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › levetiracetam

levetiracetam

4 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of levetiracetam

49 trials tracked of levetiracetam: 26 in phase 3 or 4 and 3 with published results. The most-cited published study has 90 citations.

49Trials tracked
26Phase 3 & 4
0Recruiting
3With published results
Phase distribution
Phase 4 11 Phase 3 15 Phase 2 14 Phase 1 5 Other / NA 4
  1. Phase 3 Established Status Epilepticus Treatment Trial Completed · 90 cited
  2. Phase 4 Open Label Safety and Efficacy Study of Levetiracetam in Patients With Epilepsy Completed · 22 cited
  3. Phase 3 Add on Lacosamide Versus High Dose Monotherapy Completed · 12 cited
  4. Phase 4 1 Week Versus 6 Weeks of Levetiracetam in Surgical Brain Tumor Patients Completed
  5. Phase 4 Levetiracetam Versus Valproate in Idiopathic Generalized Tonic-clonic Seizures Completed
  6. Phase 4 Seizure Prophylaxis in Aneurysm Repair Completed
Show 43 more trials
  1. Phase 4 Assess Safety and Efficacy of Levetiracetam(LEV;Keppra)for Seizure Prevention Completed
  2. Phase 4 Study on the Treatment of Elderly Patients With Older and Newer Antiepileptic Drugs Completed
  3. Phase 4 Comparison of Keppra and Clonidine in the Treatment of Tics Completed
  4. Phase 4 Effectiveness of Levetiracetam in the Treatment of Body Dysmorphic Disorder Completed
  5. Phase 4 Levetiracetam Versus Oxcarbazepine as Monotherapy to Evaluate Efficacy and Safety in Subjects With Newly or Recently Diagnosed Partial Epilepsy Completed
  6. Phase 4 Levetiracetam: The Anti-Convulsant of Choice for Elderly Patients With Dementia Completed
  7. Phase 4 Levetiracetam Versus Topiramate as Adjunctive Therapy to Evaluate Efficacy and Safety in Subjects With Refractory Partial Onset Seizures Completed
  8. Phase 3 Open-label, Randomized, Active-controlled Study of LEV Used as Monotherapy in Patients With Partial-Onset Seizures Completed
  9. Phase 3 An Open Label Study of L059 (Levetiracetam) in Japanese Epilepsy Subjects With Generalized Tonic-clonic Seizures Completed
  10. Phase 3 Monotherapy With Levetiracetam in Patients Suffering From Epilepsy. Completed
  11. Phase 3 Follow-up Study of L059 (Levetiracetam) in Epileptic Patients With Partial Onset Seizures by Open Label Method Completed
  12. Phase 3 A Study to Investigate the Safety of the Drugs Topiramate and Levetiracetam in Treating Children Recently Diagnosed With Epilepsy Completed
  13. Phase 3 A Study Of The Safety And Efficacy Of Levetiracetam (Keppra®) (Ucb L059) In Children With Epilepsy Completed
  14. Phase 3 A Study of Levetiracetam as Monotherapy or Adjunctive Treatment of Partial Seizures in Pediatric Epileptic Subjects Ranging From 1 Month to Less Than 4 Years of Age Completed
  15. Phase 3 A Study of Levetiracetam in Japanese Pediatric Patients With Generalized Tonic-clonic Seizures Completed
  16. Phase 3 Pregabalin Versus Levetiracetam In Partial Seizures Completed
  17. Phase 3 Follow up Trial for Keppra (Levetiracetam) as Monotherapy in Patients With Newly Diagnosed Epilepsy Coming From N01175 (NCT00175903). Completed
  18. Phase 3 A Long Term Follow up Administration Study of L059 (Levetiracetam) in Epilepsy Patients With Partial Onset Seizures Completed
  19. Phase 3 An Open Label Study of Levetiracetam in Japanese Pediatric Patients With Partial Seizures Completed
  20. Phase 3 A Double-blind, Placebo-controlled Study of Levetiracetam in Epilepsy Patients With Generalized Tonic-clonic Seizures (Except Partial Seizures Evolving to Secondarily Generalized Seizures) Completed
  21. Phase 2 Levetiracetam for the Treatment of Alcohol Dependence and Anxiety Completed
  22. Phase 2 Enteral Levetiracetam For Seizure Control In Pediatric Cerebral Malaria Completed
  23. Phase 2 Reducing Hippocampal Hyperactivity and Improving Cognition in Schizophrenia Completed
  24. Phase 2 Open-label Study of Levetiracetam Intravenous Infusion in Children (1 Month-4 Years Old) With Epilepsy Completed
  25. Phase 2 Dosing of Levetiracetam (Keppra) in Neonates Completed
  26. Phase 2 Efficacy of Levetiracetam in Cocaine-Abusing Methadone Maintained Patients Completed
  27. Phase 2 Efficacy of Levetiracetam in Oromandibular and Cranial Dystonia Completed
  28. Phase 2 Therapy for Children With Advanced Stage Neuroblastoma Completed
  29. Phase 2 Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma Completed
  30. Phase 2 An Open Label Study of L059 Intravenous (IV) in Japanese Epilepsy Subjects With Partial Onset Seizures Completed
  31. Phase 2 Levetiracetam in Early Psychosis Completed
  32. Phase 2 Levetiracetam for Alzheimer's Disease-Associated Network Hyperexcitability Completed
  33. Phase 2 Open-label Study of Levetiracetam Intravenous Infusion in Children (4-16 Years Old) With Epilepsy Completed
  34. Phase 2 Levetiracetam to Prevent Post-Traumatic Epilepsy Completed
  35. Phase 1 A Study in Participants With Epilepsy, to Evaluate the Pharmacokinetics, Safety and Tolerability of Oxcarbazepine on Padsevonil Completed
  36. Phase 1 Levetiracetam 1000 mg Under Non-Fasting Conditions Completed
  37. Phase 1 Levetiracetam 1000 mg Under Fasting Conditions Completed
  38. Phase 1 Levetiracetam 750 mg Tablets Under Fasting Conditions Completed
  39. Phase 1 Levetiracetam 750 mg Tablets Under Non-Fasting Conditions Completed
  40. N/A Cognitive Effects of Treatment of Interictal Discharges Completed
  41. N/A Levetiracetam in the Management of Bipolar Depression Completed
  42. N/A Premenstrual Dysphoric Disorder and Antiepileptic Drugs Completed
  43. N/A A Clinical Study Examining the Safety and Effectiveness of a New Medication (Keppra®) for the Prevention of Migraine Headaches Completed

Showing the 49 most-cited and recently-updated of 49 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Systematic review and meta-analysis of levetiracetam efficacy in pediatric epilepsy patients
Pediatrics Meta-analysis
Systematic review and meta-analysis of levetiracetam efficacy in pediatric epilepsy patients Levetiracetam shows seizure benefits over placebo in children with epilepsy
This systematic review and meta-analysis evaluated levetiracetam (LEV) in patients 16 years or younger with epilepsy. The analysis included …
A large analysis found levetiracetam improved seizure freedom and responder rates compared to placebo in children, though it did not consist…
May 28, 2026
Systematic review finds levetiracetam linked to psychobehavioral adverse effects in epilepsy
Neurology Sys. Review
Systematic review finds levetiracetam linked to psychobehavioral adverse effects in epilepsy Levetiracetam linked to irritability and aggression in epilepsy patients
This systematic review synthesizes evidence on psychobehavioral adverse effects (PBAEs) of levetiracetam in epilepsy.
A review finds levetiracetam for epilepsy is tied to higher rates of irritability and aggression, with some patients stopping the drug becau…
Frontiers Apr 22, 2026
Review of emulated trial finds levetiracetam continuation associated with lower 90-day mortality after stroke
Neurology
Review of emulated trial finds levetiracetam continuation associated with lower 90-day mortality after stroke Taking This Common Stroke Medicine Might Save Lives After Discharge
This review summarizes an emulated target trial using Medicare claims (2008-2021) comparing continued versus discontinued outpatient levetir…
Older adults who kept taking a common seizure medication after a stroke had a lower risk of dying within three months.
medRxiv Apr 21, 2026
FDA Approves Levetiracetam for Partial-Onset, Myoclonic, and Primary Generalized Tonic-Clonic Seizures
Neurology FDA Approval
FDA Approves Levetiracetam for Partial-Onset, Myoclonic, and Primary Generalized Tonic-Clonic Seizures FDA approves a seizure medicine called levetiracetam for children and adults
Levetiracetam is approved for the treatment of partial-onset seizures in patients 1 month and older, and as adjunctive therapy for myoclonic…
The FDA now approves levetiracetam for children as young as one month and adults to treat specific seizure types.
FDA Apr 10, 2026